ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results
2026 Prix Galien Awards Recognize Major Advances in Cancer Treatment, Screening and Immunotherapy
FASCO 2027: Recognizing Dedication to Oncology
Can the Tumor’s Own B Cells Reveal the Next Immunotherapy Target?
Adding SPICE to SBRT: Intentional Hotspots Associated with Improved Local Control in Early-Stage NSCLC
Carla Ferrell and Sista Strut 2026: Breast Cancer Awareness Mission
Top Gastroesophageal Cancer Updates From ESMO 2026
Re-Irradiation in Pediatric CNS Tumors: Balancing a Second Chance of Cure Against Long-Term Toxicity
